Clinical trials of the DNTM inhibitor azacytidine and the EZH2 inhibitors tazemetostat and GSK126 are currently being conducted with respect to various malignancies; therefore, these agents are also expected to confirm the efficacy of the anti-tumor immune response in combination with anti-PD-1/PD-L1 antibody treatment. Here, EZH2 is linked to neoplasm.